

# **CLINICAL CASES**

## **Expertise - Innovation - Prevention**



## +400 USERS

of the medical device pOpmètre®

## **DIFFERENT SPECIALISTES**

- Hospitals & Clinics
- General Practionners
- Cadiologists
- Diabetologists
- Nephrologists
- Somnologist





## FOR WHAT TYPE OF PATIENTS Do you carry out pOpmètre® measurement?

The patients most concerned by pOpmeter measurements are those most at risk of cardiovascular disease as well as diabetics and hypertensives.

For diabetics it is the impact of glycation on vascular remodeling that is of interest as well as ABI.

For hypertensives, the risk of organ damage is studied as well as central pressure in order to best adjust treatments.







## THE MAIN USES OF THE POPMETRE® ?

- Earlier and more precise assessment of cardiovascular risks.
- Better stratification of « at risk » patients.
- Educational tools to improve caregiver/patient communication and empower patient in behavior changes decisions.
- Personalization of the treatment and prevention approach.







## **ADD ON POPMETRE FOR HYPERTENSIVE PATIENTS**

- PWV measurement : 2018 ESC(1) and 2023 ESH(2) guidelines to prevent the risk of organ damages and identify most at risk patients.
- Central pressures measurement allows us to better understand the reality of the cardiac load (3).
- A central pulse pressure (the difference between systolic and diastolic blood pressure at the aorta and is an indicator of arterial stiffness) above 50 mmHg 4 is generally considered elevated and may indicate an increased risk of cardiovascular disease. And suggest a significant increase in the workload of the heart and a decrease in the efficiency of blood perfusion in peripheral organs and tissues. This may require further assessment to identify the underlying cause of increased arterial stiffness and to implement strategies to reduce cardiovascular risk, such as lifestyle modification, pressure control blood pressure.



<sup>1.</sup> https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-6/ESH-ESC-Guideline-for-the-management-of-hypertension-Title-ESH-ESC-Guideline

https://www.portailvasculaire.fr/sites/default/files/docs/2023\_esh\_guidelines\_for\_the\_management\_of\_arterial.271\_0.pdf 3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029873/

<sup>4.</sup> https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164777/

## **PATIENT CASE N°1 - 37YO**

#### • Family history of cardiovascular diseases

- Overweight
- Smoker (>20 cigarettes/day)
- No known cholesterol or diabetes
- Known but untreated hypertension
- The PWV measured is more than 10 m per second which places the patient at "high risk".
- His corrected central pressure is a little better than the peripheral and takes him from stage 1 hypertension to "normally high" blood pressure.
- The patient is a smoker without physical activity
- The patient, already aware of the cardiovascular risks linked to his family history and his overweight and his addiction to tobacco, was particularly sensitive to the notion of arterial age.
- He engaged in a process of self-measurement of blood pressure and a smoking cessation with resumption of physical activity.







## **PATIENT CASE N°1**

« I knew I had to be careful but I was putting it off until later since I'm 37 years old. Blood pressure seemed abstract to me but telling myself that my arteries are 77 years old made me realize that I need to change ! »

Ali – Patient



#### Interventions Using Heart Age for Cardiovascular Disease Risk Communication: Systematic Review of Psychological, Behavioral, and Clinical Effects

Carissa Bonner <sup>1</sup><sup>(0)</sup>; Carys Batcup <sup>1</sup><sup>(0)</sup>; Samuel Cornell <sup>1</sup><sup>(0)</sup>; Michael Anthony Fajardo <sup>1</sup><sup>(0)</sup>; Anna L Hawkes <sup>2</sup><sup>(0)</sup>; Lyndal Trevena <sup>1</sup><sup>(0)</sup>; Jenny Doust <sup>3</sup><sup>(0)</sup>





# 66

## ADD ON VASCULAR AGE - ARTERIAL AGE : CLINICAL RELEVANCE ?

## Numerous clinical studies demonstrate the importance of arterial stiffness.

- 1. <u>https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-6/</u> <u>ESH-ESC-Guideline-for-the-management-of-hypertension-Title-ESH-ESC-</u> <u>Guideline</u>
- 2. <u>https://www.portailvasculaire.fr/sites/default/files/</u> docs/2023\_esh\_guidelines\_for\_the\_management\_of\_arterial.271\_0.pdf
- 3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029873/
- 4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164777/

## VASCULAR AGE

It is data that is universally understood by patients.(5)

Have received dietary advice.

Deterioration of vascular age.





(5)https://pubmed.ncbi.nlm.nih.gov/24491403/



## **+4.5 years**



## **GROUPE B**

Have received dietary advice and their cardiovascular risk in the form of arterial age.

Improvement in vascular age.

1,5 years

Four times more people quit smoking in this group.





### **PATIENTE N°2 - 58yo**

- Treated but uncontrolled grade 3 hypertension (compliance problem)
- Former smoker obese (BMI 35)
- High cholesterol T2DM
- The PWV measured is more than 20 m per second which places the patient at "high risk".
- Central pressure confirms the diagnosis of hypertension and especially pulse pressure above 50 mmHg alerts to structural damage at the vascular level. Arterial stiffness and high blood pressure put the patient at risk of organ damage.
- The priority is the adaptation of treatments towards a family of antihypertensives whose effectiveness on arterial stiffness is greater.
- The patient is made aware of the importance of compliance and uses an alarm on his smartphone to think about his treatment. Given the high LDL cholesterol, the prescription of antihypercholesterolemic drugs is also initiated - it will also act on arterial stiffness to reduce it.
- Arterial age is an opportunity to resume communication with the patient about the risks involved and the behavioral changes to initiate - the patient is sent for a calcium score and to a dietitian to initiate a change in diet towards a Mediterranean diet.





![](_page_10_Picture_0.jpeg)

## **PATIENT CASE N°2**

« While I sometimes had the impression of being in a dead end with some of my patients in my cardiovascular consultation, the use of the pOpmetre and the concept of arterial age allow renewed exchanges, easier, more motivating for everyone. Telling them that we have the age of our arteries, that we can now measure it and why it is important to do so, but also telling them that we can improve it... it's a game changer! »

Pr A - cardiologist

![](_page_10_Picture_5.jpeg)

![](_page_10_Picture_6.jpeg)

![](_page_11_Picture_0.jpeg)

## ASSOCIATED SCIENTIFIC PUBLICATION

"Outpatient measurement of arterial stiffness in patients with type 2 diabetes and obesity"

POPULATION

- Obese without T2DM
- Obese with T2DM
- T2DM without obesity
- Healthy control

CONCLUSION

Outpatient-measured ftPWV was correlated with age, SBP, and ABI. It was higher in patients with T2DM and obesity compared with healthy controls. The highest ftPWV was observed in patients with both T2DM and obesity.

![](_page_11_Picture_10.jpeg)

Lien de la publication

![](_page_11_Picture_12.jpeg)

![](_page_12_Picture_0.jpeg)

![](_page_12_Picture_1.jpeg)

### **ADD ON Arterial stiffness impact on framingham's score**

(A) all- cause mortality, (B) fatal stroke or death from coronary heart disease (cardiovascular mortality) and (C) fatal or non-fatal stroke, death from non-fatal coronary artery disease or myocardial infarction (composite criterion). Low (10-year estimated risk of the broader 15%), intermediate-high (15%  $\leq$  and < 20%), or high ( $\geq$  20%).

Julie K.K. Vishram-Nielsen. Hypertension. La vitesse de l'onde de pouls estimée ajoute-telle des informations pronostiques ?, Volume : 75, Numéro : 6, Pages : 1420-1428, DOI : (10.1161/HYPERTENSIONAHA.119.14088) © 2020 American Heart Association, Inc.

- Ten-year incidence rate by estimated pulse wave velocity (ePWV; <9.4 m/
- s=low and ≥9.4 m/s=high) and Framingham Risk Score (FRS) category for
- composite cardiovascular endpoint < 10%), low intermediate (10%  $\leq$  and <

![](_page_12_Figure_13.jpeg)

![](_page_12_Figure_14.jpeg)

## **PATIENT CASE N°3 36yo**

- No cardiovascular risk factors
- Slightly overweight

66

- No physical activity
- Diet mainly based on processed foods and a lot of soda
- The PWV measured is on the borderline zone for this patient.
- No specific risk factors but "bad" lifestyle
- The patient is made aware through the arterial age measured at 51 years (+15 years) and becomes aware that without being pathological his behaviors put him on the wrong path.
- He clicks with the measure and wants to initiate changes
- He is aware of the importance of adopting a healthy diet and taking up physical activity.

![](_page_13_Picture_10.jpeg)

![](_page_13_Figure_11.jpeg)

![](_page_14_Picture_0.jpeg)

![](_page_14_Picture_4.jpeg)

## **CAS PATIENT N°3**

"As a general practitioner, I follow my patients over time. I use pOpmeter on all types of patients even if I specialize in athletes. It is very satisfying to see the progress on PWV, and therefore arterial age, which occurs quickly during changes in health and diet behavior!»

Dr G - GP

![](_page_14_Picture_8.jpeg)

![](_page_15_Picture_0.jpeg)

## ASSOCIATED SCIENTIFIC PUBLICATION

#### "MEASURING ARTERIAL STIFFNESS WITH POPMÈTRE® IN CARDIAC REHABILITATION PROGRAM"

Hasan Obeidet et al.

December 2016

#### POPULATION

- CVD subjects undergoing physical activity program
- Coronary artery disease
- Valvular
- Heart failure
- Other

#### RESULTS

PWV decreased from 9.16+/-3.0 to 8.39+/-2.5 m/s (p<0.008). We found a positive correlation with age (rZ0.38 p<0.0003) and inverse correlation with maximal workload (rZ-0.34 p<0.001) and 6MWT (rZ-0.22 p<0.003). Maximal physical capacity and 6MWT correlated with PWV measured with pOpmetre, and a current CR program seems to improve the arterial stiffness in a cardiac population.

Link of the study

![](_page_15_Picture_14.jpeg)

![](_page_15_Picture_15.jpeg)

![](_page_16_Picture_0.jpeg)

## **ADD ON PHYSICAL ACTIVITY**

Physical activity is associated with reduced cardiovascular disease risk, mainly through effects on atherosclerosis. Aortic stiffness may be an alternative mechanism. We examined whether patterns of physical activity and sedentary behavior are associated with rate of aortic stiffening.

Conclusions : Higher levels of moderate-tovigorous physical activity and avoidance of sedentary behavior were each associated with a slower age-related progression of aortic stiffness independent of conventional vascular risk factors.

https://www.ahajournals.org/doi/10.1161/JAHA.117.005974

![](_page_16_Figure_7.jpeg)

## **66 PATIENT CASE N°4 54yo**

- Patient aged 54
- No risk factors
- Good diet
- Sporty
- The PWV measured is on the optimal zone for this patient.
- The patient is comforted in his lifestyle, diet and sport.

![](_page_17_Picture_7.jpeg)

VAneije	Review report		
DATE 15/11/2023 11:12:06 CLINICAL DATA			
NAME HERMAN HEIGHT 173 cm AGE 54 years	Optimal Normal	Borderline High risk	PWV 6.1 m/s** Optimal VASCULAR AGEIN 23 years -31 years -31 years
Right	CENTRAL PRESSURES Systolic 110 mmHg	Diastolic 81 mmHg	Pulse 28 mmHg
PRESSURES	HEART RATE	TRANSIT TIME 95 ms	ANKLE BRACHIAL INDEX 1.14

![](_page_17_Picture_9.jpeg)

![](_page_18_Picture_0.jpeg)

### **PATIENT CASE N°4**

« It's awesome ! It's so satisfying and motivating. Usually I go to the doctor and he just tells me that everything is normal... that's good, but I've always been doing sports, I'm careful about what I eat, I've never smoked and I almost never drink... it's cool to see that these lifestyle choices make me better than "just normal". When I tell my wife that I'm 23... »

H - Patient

![](_page_18_Picture_5.jpeg)

#### Extreme vascular ageing phenotypes: EVA and SUPERNOVA

![](_page_19_Figure_1.jpeg)

## ADD ON **ARTERIAL AGE IS ESSENTIAL**

**EVA** : Early Vascular Aging **SUPERNOVA** : Super Normal Vascular Aging

In conclusion, we demonstrated that individuals whose vascular age is lower than their chronological age (the SUPERNOVA phenotype) showed an ageand sex-adjusted rate of cardiovascular events about 40% lower than individuals with normal VA, despite a greater chronological age and a substantially similar burden of cardiovascular risk factors. Furthermore, the use of EVA classification may help identifying individuals at premature risk of coronary events for nonconventional cardiovascular risk factors, particularly women. In the future, dissecting the environmental and genetic mechanisms explaining the SUPERNOVA phenotype will help identify new therapeutic targets for successful vascular aging and target those environmental factors beyond classical cardiovascular risk factors which may favor it. However, the correct identification of EVA is crucial to set up public health strategies for prevention and ameliorate prognosis of individuals showing accelerated vascular aging not captured by standard assessment of risk.

![](_page_19_Figure_7.jpeg)

## **SCIENTIFIC BOARD**

![](_page_20_Picture_1.jpeg)

Pr Pierre Boutouyrie Head of the Clinical Pharmacology Department

Georges Pompidou Hospital - Paris

![](_page_20_Picture_4.jpeg)

Pr Faouzi Addad Cardiologist

Former President of the Tunisian Society of Cardiology

![](_page_20_Picture_7.jpeg)

Pr Atul Pathak Chief of Cardiology, Head of Department

Princesse Grace Hospital - President of the French Society of Arterial Hypertension

![](_page_20_Picture_10.jpeg)

![](_page_20_Picture_11.jpeg)

![](_page_20_Picture_12.jpeg)

![](_page_20_Picture_14.jpeg)

![](_page_20_Picture_16.jpeg)

![](_page_20_Picture_17.jpeg)

Dr François Sarkozy **President of FSNB** Health & Care

Pediatrician and former resident of the Hospitals of Paris

![](_page_20_Picture_20.jpeg)

Pr Stéphane Laurent Head of the Clinical Pharmacology Department

Georges Pompidou Hospital - Paris

![](_page_20_Picture_23.jpeg)

Dr Imad Abi Nasr Cardiologist MD, FESC Department of Medical Cardiology

Bizet Clinic - Paris Scientific Director Axelife

![](_page_20_Picture_26.jpeg)

#### **Pr Roland Asmar** Cardiologist

Former President of the International Society of Vascular Health

![](_page_20_Picture_29.jpeg)

Dr Yannick Guillodot Sports physician

Former Scientific Secretary of the French Society of Sports Traumatology

![](_page_20_Picture_32.jpeg)

Pr Michel Marre Head of the Encrinology **Diabetology Nutrition** Department

Bichat Claude Bernard Hospital - Paris

![](_page_20_Picture_35.jpeg)

### **QUOTES FROM HCPs USING THE POPMETRE®**

### DR J Dr J - GP

« I use pOpmetre a lot. This allows me to present this cardiovascular consultation to the patient in a different way. I look at cardiovascular risk in a more global way and I better identify my patients most at risk, whom I take care of in a more personalized way by using arterial age to initiate behavioral changes.»

## Pr B

### Pr B - Cardiologist

« I use pOpmetre a lot. This allows me to present this cardiovascular consultation to the patient in a different way. I look at cardiovascular risk in a more global way and I better identify my patients most at risk, whom I take care of in a more personalized way by using arterial age to initiate behavioral changes.»

![](_page_21_Picture_6.jpeg)

### Dr H

#### Dr H - nephrologist

« For a patient with kidney failure, high PWV values revealed by the pOpmeter may indicate deterioration in the elasticity of the arteries, often due to calcium buildup and other factors related to chronic kidney disease. This information is crucial, because it allows us to intervene earlier with targeted therapeutic strategies, aimed at reducing cardiovascular risk.»

#### Dr F

#### Dr F – GP - somnologist

«Sleep disorders can have a significant impact on cardiovascular health. In our practice, we have incorporated the use of the pOpmeter to assess pulse wave velocity (PWV) in patients with sleep disorders, such as I sleep apnea. This tool allows us to complete our clinical evaluation by identifying patients who, in addition to their sleep disorders, may be at risk of cardiovascular complications. As a result, we can adapt our care, not only by treating sleep disorders but also by taking preventive measures for cardiovascular health. Integrating the pOpmeter into the assessment of our patients strengthens our holistic approach, helping us improve their overall quality of life.»

![](_page_21_Figure_13.jpeg)

## RECOMMENDATIONS FROM HCPS USING THE POPMETRE®

![](_page_22_Picture_1.jpeg)

## Pr Asmar Cardiologist

"In my opinion, the main advantage of the pOpmètre<sup>®</sup> is that it is not operator- dependent. You put the pOpmètre<sup>®</sup> on and let it work, unlike other devices on the market."

"In one year, I took over 1,500 measurements" and observed a significant improvement in the arterial age of the 100 patients treated, thanks to the adaptation of the treatment."

![](_page_22_Picture_6.jpeg)

![](_page_22_Picture_7.jpeg)

![](_page_22_Picture_8.jpeg)

### Pr Addad Cardiologist

![](_page_22_Picture_10.jpeg)

### Dr Guicheteau **General Practioner**

"The pOpmètre® makes it possible to carry out an absolutely painless examination, which is therefore easily accepted by patients. It's a technical procedure that can be integrated into the patient's care and for which it's possible to delegate tasks."

![](_page_22_Picture_13.jpeg)

![](_page_23_Picture_0.jpeg)

![](_page_23_Picture_1.jpeg)

## PARTNERS THEY TRUST US

![](_page_23_Picture_7.jpeg)

![](_page_24_Picture_0.jpeg)

# THANK YOU

## ww.axelife.com contact@axelife.com

Fabriqué par Axelife, le pOpmètre<sup>®</sup> est un dispositif médical de classe lla, produit de santé réglementé qui porte, au titre de cette réglementation, le marquage CE 1282. Il mesure la rigidité artérielle. Pour toute information complémentaire, reportez-vous à la notice d'utilisation.

![](_page_24_Picture_4.jpeg)